Skip to main content

Table 2 Comparison of clinical, laboratory and radiological data among cases and controls

From: Effect of zinc supplementation on growth Hormone Insulin growth factor axis in short Egyptian children with zinc deficiency

  Cases Controls t p
  (N = 50) (N = 50)   
Age (years) 6.5 ± 3.05 6.7 ± 2.05 1.2 0.11
  (3.2 -10.9) (3.5-10.8)   
Sex , n(%)     
Males 27(54 %) 28 (56 %) 1.11 0.23
Females 23(46 %) 22(44 %)   
Height SDS -3.12 ± 0.2 +1.04 ± 0.5 19.88  <0.001***
(-2.15- -4.21) (+0.99 - +1.65)   
GV after Zn (cm/3 months) 0.55 ± 0.1 0.61 ± 0.1 0.82 0.11
(0.1-2.23) (0.2-3.13)   
GV SDS +1.01 ± 0.2 +1.21 ± 0.1 1.3 0.15
(-0.5 - +2.11) (-0.3 - +2.31)   
Weight SDS -1.88 ± 0.62 -1.02 ± 0.71 1.7 0.2
(-2.01 - +0.55) (-1.20 - +1.45)   
BMI (kg/m2) 16.41 ± 1.56 17.51 ± 0.52 1.0 0.3
(14.33-20.12) (14.33-20.12)   
BMI SDS -1.77 ± 0.41 -1.02 ± 0.31 1.99 0.082
(-2.10- -0.78) (-1.30 - +0.23)   
Serum Zn (μg/dl) 56.76 ± 7.90 136.70 ± 8.10 22.5 <0.001***
(37.52-93.11) (123.17-149.50)   
Peak GH after insulin stimulation (ng/ml) 10.65 ± 2.01 14.25 ± 3.01 6.50 0.04*
(7.61-13.20) (10.91-18.30)   
Peak GH after clonidine stimulation (ng/ml) 11.14 ± 1.41 15.24 ± 2.11 6.81 0.041*
(6.92-14.11) (11.12-19.21)   
IGF-1 (ng/ml) 96.72 ± 11.5 286.62 ± 12.5 12.86  <0.001***
(36.52-115.69) (198.72-325.19)   
IGF-1 SDS -2.46 ± 0.11 +1.46 ± 0.21 17.66 <0.001***
(-3.22- +0.55) (+0.89 - +1.85)   
IGFBP-3 (ng/ml) 2436.12 ± 392 3936.22 ± 194 15.12 <0.001***
(1195.45-3898.15) (3721.45-4498.15)   
-BA (years) 3.7 ± 1.05 6.8 ± 1.6 6.11 0.020*
(1.81-9.25) (3.31-11.25)   
-BA SDS -1.75 ± 1.14 +0.85 ± 1.20 13.24 <0.001***
(-2.44 - +0.22) (+1.04 - +0.22)   
  1. Results are expressed as mean ± SD and range frequency and percentage, *p < 0.05, **p < 0.01, ***p < 0.001, GHD: growth hormone deficiency, SDS: Standard deviation score, GV: growth velocity, Zn: zinc, BMI: Body mass index, Zn: zinc, GH: Growth hormone, IGF-1: Insulin like growth factor-1, IGFBP-3: Insulin like growth factor binding protein-3, BA: bone age.